Monthly Prescribing Reference

Evolocumab Reduces CV Events In High-Risk Adults Without Prior Stroke, Heart Attack

Findings that evolocumab significantly reduced the risk of major adverse CV events in adults at high CV risk without prior heart attack or stroke vs placebo. Topline data were announced from a phase 3 ...
TCTMD

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Oral semaglutide (Rybelsus) can now be used to reduce major adverse cardiovascular events in patients with type 2 diabetes and high cardiovascular risk, following the US Food and Drug Administration’s ...
Healio

Evolocumab lowers risk for first major cardiovascular events

Please provide your email address to receive an email when new articles are posted on . Evolocumab is the first PCSK9 inhibitor to demonstrate effectiveness in primary and secondary prevention ...
Healio

Sleep study-defined OSA subgroups modify cardiovascular risk with CPAP

Please provide your email address to receive an email when new articles are posted on . An OSA-related heart rate response greater than 9.4 bpm or hypoxic burden greater than 87.1% minutes/hour ...